Chiron's Menjugate approved in Canada

26 April 2001

Health Canada's Bureau of Biologics and Radiopharmaceuticals hasgranted approval for Chiron to market its Menjugate vaccine to prevent disease caused by the bacteria Neisseria meningitidis serogroup C. In Canada, Merck Frosst will be the exclusive distributor of the vaccine, which was first licensed in the UK last year (Marketletter March 6, 2000). Chiron is also applying for registration throughout the European Union by means of the Mutual Recognition procedure. First-quarter sales of the vaccine fell to $29 million from $60 million a year earlier, on lower shipments to the UK, which had suffered a meningitis outbreak in the same period of 2000.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight